2014 Sep;155(9):3434-47
In response to growing criticism of the cost of their drugs, Novo Nordisk, the company that manufactures Ozempic and Wegovy, reported last year that rebates and other fees (across all payers) accounted for about 40% of the cost of the two drugs and that they expected rebates to grow
J.HusainM
Most current-generation weight loss drugs - GLP-1s, amylins - help patients lose weight by, primarily, suppressing appetite in turn restricting calorie intake
Despite their growing popularity 2225 (e.g., GLP-1 RA prescriptions increased, 3% between September and December 2023, 21% between December 2023 and March 2024, 8% between March and June 2024, and 12% between June and September 2024 26 ) and the medias portrayal of expected and unexpected benefits of GLP-1 RAs, 27,28 there exists a paucity of real-world data examining their downstream health effects
Yajima T, Yajima K, Takahashi H, Yasuda K